Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
Feature|Videos|December 17, 2025

De-risk Biologic Development: Engineering Flexibility from Early Development to Launch

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Key Objectives

  • Understand how AI, automation, and high-throughput process development can reduce risk and accelerate early- and late-pha
  • Identify the role of digitization, inline analytics, and quality-by-design principles in enabling scalable and regulatory-ready bioprocesses.
  • Evaluate how standardized manufacturing facilities can improve supply chain resilience and support commercial production.

Biologics development carries inherent risk, particularly in early phases where funding constraints make speed, cost reduction, and efficient process development critical. High-throughput experimentation, automation, and AI-driven tools are increasingly being applied to bioreactor monitoring, inline analytics, and experimental design to enable faster development while supporting scalable, quality-by-design processes. Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, discusses how harmonized manufacturing facilities and end-to-end digitization are further reducing supply chain risk and enabling agile, global commercial manufacturing.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.